Unique Ingredient Identifier KH7I04HPUU is listed as a ingredient substance
| RN | 7558-80-7 |
| EC | 231-449-2 |
| NCIT | C66550 |
| RXCUI | 349753 |
| MF | Na.H2O4P |
| INCHI KEY | AJPJDKMHJJGVTQ-UHFFFAOYSA-M |
| SMILES | [Na+].OP(O)([O-])=O |
UNII KH7I04HPUU SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS is commonly included in medications in the following forms.
| Route | Dosage Form | Potency |
|---|---|---|
| AURICULAR (OTIC) | SOLUTION | 0.13 % |
| AURICULAR (OTIC) | SUSPENSION | NA |
| BUCCAL | FILM | 1.09 MG |
| IM - IV | INJECTABLE | 0.16 % |
| IM - IV | INJECTION | 1.28 % |
| IM - IV | POWDER, FOR INJECTION SOLUTION | 1.28 % |
| IM - IV | SOLUTION, INJECTION | 0.62 % |
| INTRA-ARTERIAL | SUSPENSION, INJECTION | 6.8 mg/1mL |
| INTRA-ARTICULAR | INJECTION | NA |
| INTRA-ARTICULAR | SUSPENSION | 0.28 % |
| INTRABURSAL | INJECTION | NA |
| INTRADERMAL | INJECTION | NA |
| INTRALESIONAL | INJECTION | NA |
| INTRALESIONAL | INJECTION, SUSTAINED ACTION | 6.59 MG/ML |
| INTRAMUSCULAR | INJECTION | 0.5 %W/V |
| INTRAMUSCULAR | INJECTION, SUSPENSION, EXTENDED RELEASE | 0.17 % |
| INTRAMUSCULAR | INJECTION, SUSTAINED ACTION | 6.59 MG/ML |
| INTRAMUSCULAR | POWDER, FOR INJECTION SOLUTION | 0.5 % |
| INTRAMUSCULAR | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | 1.2 % |
| INTRAMUSCULAR | SOLUTION, INJECTION | NA |
| INTRAMUSCULAR | SUSPENSION | 0.28 % |
| INTRAMUSCULAR | SUSPENSION, INJECTION | 0.75 % |
| INTRAOCULAR | INSERT | 1.08 % |
| INTRASYNOVIAL | INJECTION, SUSTAINED ACTION | 6.59 MG/ML |
| INTRAVASCULAR | INJECTION | 0.013 % |
| INTRAVENOUS | INJECTION | 0.5 % |
| INTRAVENOUS | POWDER, FOR INJECTION SOLUTION | 0.71 % |
| INTRAVENOUS | SOLUTION | 4 % |
| INTRAVESICAL | SOLUTION | 0.115 MG |
| IV(INFUSION) | INJECTION | 0.5 % |
| IV(INFUSION) | POWDER, FOR INJECTION SOLUTION | 1.28 % |
| NASAL | SPRAY, METERED | 0.019 % |
| OPHTHALMIC | DROPS | 0.35 % |
| OPHTHALMIC | SOLUTION | 0.78 % |
| OPHTHALMIC | SOLUTION, DROPS | 0.72 % |
| OPHTHALMIC | SUSPENSION | 0.65 % |
| OPHTHALMIC | SUSPENSION, DROPS | 0.056 % |
| ORAL | CONCENTRATE | NA |
| ORAL | SOLUTION | 40 MG |
| ORAL | SUSPENSION | 32.5 MG/5ML |
| ORAL | SYRUP | 0.07 % |
| ORAL | TABLET | 4.18 MG |
| ORAL | TABLET, DELAYED ACTION, ENTERIC COATED | 23.4 MG |
| ORAL | TABLET, SUSTAINED ACTION, FILM COATED | 30.97 MG |
| SOFT TISSUE | INJECTION, SUSTAINED ACTION | 6.59 MG/ML |
| SUBCUTANEOUS | INJECTION | 3.31 % |
| SUBCUTANEOUS | POWDER, FOR INJECTION SOLUTION | 0.08 % |
| SUBCUTANEOUS | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | 0.11 % |
| SUBCUTANEOUS | SOLUTION, INJECTION | 0.2 % |
| TOPICAL | EMULSION, CREAM | 0.3 %W/W |
| TOPICAL | GEL | 0.3 %W/W |
| TOPICAL | LOTION | 0.2 %W/W |
| TOPICAL | LOTION | NA |
| TOPICAL | SHAMPOO, SUSPENSION | 1 %W/V |
| TOPICAL | SOLUTION | 0.47 %W/V |
| VAGINAL | EMULSION, CREAM | ADJPH |